Breckenridge Launches Tofacitinib Tablets, a Generic Alternative to Pfizer’s Xeljanz

Breckenridge Unveils Tofacitinib Tablets: A New Hope for Patients

Breckenridge Pharmaceutical, Inc., the U.S. arm of Towa International, has recently announced the launch of Tofacitinib Tablets, marking the introduction of a generic version of the widely recognized rheumatoid arthritis treatment Xeljanz® by Pfizer. This development signifies a significant stride in providing accessible medications for patients battling chronic inflammatory diseases.

Tofacitinib tablets, categorized as disease-modifying antirheumatic drugs (DMARDs), operate as Janus kinase (JAK) inhibitors. These medications work by obstructing the activity of JAK enzymes, pivotal players in transmitting signals from cytokine and growth factor receptors to cellular processes. As such, they play a crucial role in modulating immune cell functions and hematopoiesis.

This generic medication is indicated for adult patients suffering from moderately to severely active rheumatoid arthritis (RA), active psoriatic arthritis (PsA), active ankylosing spondylitis (AS), and moderately to severely active ulcerative colitis (UC). Notably, Tofacitinib is designed for individuals who have either experienced an inadequate response or have shown intolerance to one or more tumor necrosis factor (TNF) blockers. TNF is associated with inflammation and, consequently, immune disorders including Crohn's disease, ulcerative colitis, and various forms of arthritis.

Furthermore, Tofacitinib Tablets afford treatment options for pediatric patients aged two years and older experiencing PsA or active polyarticular juvenile idiopathic arthritis under similar clinical circumstances. The tablets are available in convenient 5 mg and 10 mg dosages, allowing healthcare providers to tailor treatments to each patient's unique needs.

Brian Guy, President and Chief Commercial Officer of Breckenridge Pharmaceutical, stated, "The launch of our generic version of Tofacitinib reflects our ongoing commitment to enhancing patient access to vital therapies for chronic inflammatory conditions, including those affecting children. We strive to alleviate financial barriers and improve the continuity of care for all patients, regardless of age."

Production of Tofacitinib Tablets takes place at Breckenridge’s advanced manufacturing facility in Martorelles, Barcelona, part of Towa International’s industrial network. This facility combines large-scale manufacturing capabilities with stringent quality standards, boasting an impressive annual output of over six billion doses. Tofacitinib Tablets will not only be distributed within the U.S. but will also be made available through Towa’s global distribution channels, ensuring accessibility in more than 40 countries worldwide.

The significance of this launch lies not only in the provision of a new generic medication, but also in the broader implications for patient care, as it reflects a commitment to affordability and continuous supply in a critical area of healthcare. Tofacitinib’s availability through Breckenridge marks a pivotal point in enhancing treatment options for chronic inflammatory conditions amidst rising healthcare costs and patient demand for effective therapies.

Towa International, headquartered in Barcelona, operates as the global center for Towa Pharmaceutical, a leading entity within Japan's generic medicine market. The organization is dedicated to the research, development, manufacturing, and distribution of high-quality generic pharmaceuticals, with an emphasis on improving overall health outcomes. As Breckenridge continues to partner with manufacturers locally and internationally, it strengthens its mission to provide patients with quality, cost-effective medical solutions.

For more information about Tofacitinib Tablets, including prescribing instructions and safety information, please visit Breckenridge Pharmaceuticals.

Conclusion

With the launch of Tofacitinib Tablets, Breckenridge Pharmaceutical takes a significant step toward offering affordable, reliable medications for chronic conditions, ensuring that patients receive the essential treatments they require for optimal health.